Lung cell immunotherapy
Year: 2017
Type: article
Abstract: Lung cancer remains the leading cause of death by cancer worldwide. Considering the severity and the spread of this type of cancer, researchers have considered research as a priority to identify a more effective treatment. In this short review it was presented the need for new treatment in advanced lung cancer identified by the unsatisfactory results obtained with chemotherapy, which reached a plateau in the first decade of the 3rd millennium. The understanding of molecular and immune mechanism in lung cancer allowed discovering target therapy and immunotherapy. At the moment, immunotherapy is represented by vaccines and checkpoint inhibitors. In this article there are described the main agents used in immunotherapy especially for non-small cell lung cancer: ipilimumab, nivolumab and pembrolizumab. In the same time, there are presented the new immune agents which are waiting to be introduced into current therapy.
Source: Oncolog-Hematolog ro
Author: Alexandru C. Grigorescu
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3021504039